Valneva SE Sponsored ADR (NASDAQ:VALN) Sees Significant Drop in Short Interest

Key Points

• Valneva SE experienced an 81.3% decrease in short interest during August, with total short interest dropping to 14,000 shares as of August 31st.
• The company reported a loss of $0.16 per share for the quarter ending August 12th, which exceeded analysts’ expectations, alongside revenues of $54.84 million.
• Several research firms have set a consensus rating of "Buy" for Valneva, with an average price target of $15.00

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) was the recipient of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 14,000 shares, a drop of 81.3% from the August 15th total of 74,900 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 71,700 shares, the short-interest ratio is presently 0.2 days. Based on an average trading volume of 71,700 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are short sold.

Valneva Price Performance

VALN traded up $0.13 during trading on Thursday, hitting $9.19. 21,069 shares of the stock traded hands, compared to its average volume of 70,225. Valneva has a twelve month low of $3.62 and a twelve month high of $12.25. The company has a market cap of $789.27 million, a price-to-earnings ratio of -9.37 and a beta of 1.79. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77. The business has a 50 day moving average price of $8.22 and a 200 day moving average price of $7.11.

Valneva (NASDAQ:VALN - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.11. The firm had revenue of $54.84 million for the quarter, compared to analysts' expectations of $46.28 million. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. Equities research analysts forecast that Valneva will post 0.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VALN has been the subject of several research reports. Jefferies Financial Group set a $14.00 price objective on shares of Valneva and gave the stock a "buy" rating in a research report on Monday, August 25th. Wall Street Zen upgraded shares of Valneva to a "hold" rating in a research report on Saturday, September 6th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Valneva in a research report on Monday, August 25th. Finally, Guggenheim dropped their price target on shares of Valneva from $14.00 to $13.00 and set a "buy" rating for the company in a research report on Monday. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $15.00.

Institutional Trading of Valneva

Hedge funds and other institutional investors have recently modified their holdings of the stock. Marex Group plc bought a new stake in shares of Valneva during the second quarter worth $64,000. GAMMA Investing LLC bought a new stake in shares of Valneva during the first quarter worth $94,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in shares of Valneva during the second quarter worth $8,240,000. Institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.